Generally speaking, the long-term development space of the pharmaceutical sector is very large. There are not many ESG funds in the market, and their establishment time is short, mainly depending on the operation level of fund managers. In fact, there is not much difference between the two. The stocks selected by the fund manager involve stocks in Shanghai, Hong Kong and Shenzhen.
As for what stocks to look at, it depends on the investment strategy of the fund manager. There is no difference between the two. The valuation of the whole sector is relatively high, and there are signs of a collective correction. In addition, the Medical Insurance Bureau recently started the second round of procurement of high-value consumables, so the decline is normal.
Brief introduction of China Merchants Pharmaceutical Fund:
Vice President of Quantitative Investment Department of China Merchants Fund expressed the market view. In the context of repeated epidemics, the attention of the pharmaceutical sector continues to increase, especially during the Spring Festival. The COVID-19 test is expected to increase, and the performance of pharmaceutical-related listed companies will increase, which is expected to further catalyze the market.
Investment in the pharmaceutical sector can continue to pay attention to the interpretation of the epidemic situation in the short term and track the catalytic role of the performance of the pharmaceutical sector. In the long run, medical insurance fee control is the long-term direction in the medical field, and enterprises in the fields of innovation and policy immunization are still the long-term allocation areas of investment in the pharmaceutical industry.